Keyword: Teva Pharmaceutical Industries
89Bio has raised $60 million to advance a stable of small molecules and biologics acquired from Teva.
DFCI's Haining to become VP, Oncology at Merck; Pfizer poaches Quest exec to spearhead digital; and Perrigo swaps CEO for former tobacco executive.
Chris Corsico left the CMO spot at Boehringer Ingelheim to fill a new role at GlaxoSmithKline: senior vice president of development.
Laquinimod was once hailed as a blockbuster heir to Copaxone but suffered a string of late-phase failures that dragged down Teva.
The FDA approved the first generic versions of Mylan’s EpiPen and EpiPen Jr, as shortages of the autoinjectors continue.
Fasinumab cleared the efficacy bar but triggered safety alarms, keeping it on the tail of Pfizer and Eli Lilly’s rival drug without dispelling doubts.
Adherium launched its digital inhaler add-on in the U.S., following a recent 510(k) clearance allowing it to sell the devices directly to consumers.
Active Biotech and Teva delivered more bad news from their clinical development of laquinimod, this time from a phase 2 trial in Huntington’s disease.
Gilead's clinical director joins Nimbus to lead discovery; Immunocore’s CMO jumps to Tmunity; Kite taps Eisai vet to lead CAR-T sales.
Teva is ending a phase 3 trial of its CGRP blocker in chronic cluster headache after an analysis showed it was unlikely to meet its primary endpoint.